

Cancer Prevention and Control CIRB Meeting Agenda

April 27, 2023

I. New Study - Initial Review

A212101, Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients with Newly Diagnosed Colorectal Cancer (Version Date 03/27/23)

II. Continuing Review

A222001, A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy (Version Date 09/14/22)

III. Continuing Review

EA8184, A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers (Version Date 07/21/22)

IV. Amendment

EA8184, A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers (Version Date 03/20/23)

V. Amendment

EAQ202, Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (Version Date 03/17/23)

VI. Amendment

URCC-18110CD, Implementing Palliative Care: Learning Collaborative vs. Technical Assistance (Version Date 02/01/23)

VII. Continuing Review

NWU20-04-01, Metformin for Chemoprevention of Lung Cancer in High-Risk Overweight or Obese Individuals (Version Date 12/22/22)

VIII. Continuing Review

EAQ172, Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis (Version Date 10/19/22)

IX. Continuing Review

NRG-CC010, A Phase III Trial of the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer (Version Date 06/14/22)
